These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34092824)

  • 1. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
    Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
    Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Stummer L; Markovic M; Maroney M
    Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brexpiprazole.
    Markovic M; Gallipani A; Patel KH; Maroney M
    Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brexpiprazole: A Partial Dopamine Agonist for the Treatment of Schizophrenia.
    Ekinci A; Ekinci O
    Rev Recent Clin Trials; 2018 Jan; 13(1):37-44. PubMed ID: 28828976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of brexpiprazole: comparison with aripiprazole.
    Stahl SM
    CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of brexpiprazole - a new antipsychotic drug from the group of dopamine D2 receptor partial agonists.
    Bieńkowski P; Wichniak A
    Psychiatr Pol; 2024 Apr; 58(2):237-248. PubMed ID: 39003508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brexpiprazole: First Global Approval.
    Greig SL
    Drugs; 2015 Sep; 75(14):1687-97. PubMed ID: 26310190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
    Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
    Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
    Bruijnzeel D; Tandon R
    Drug Des Devel Ther; 2016; 10():1641-7. PubMed ID: 27274197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
    Nelson JC; Weiller E; Zhang P; Weiss C; Hobart M
    J Affect Disord; 2018 Feb; 227():103-108. PubMed ID: 29055257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
    Citrome L
    Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preclinical pharmacological profiles and clinical efficacy of the novel antipsychotic drug brexpiprazole (REXULTI
    Suzuki M; Niidome K; Maeda K; Kikuchi T; Usami T; Futamura T
    Nihon Yakurigaku Zasshi; 2019; 154(5):275-287. PubMed ID: 31735758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder.
    Cha DS; Luo X; Ahmed J; Becirovic L; Cha RH; McIntyre RS
    Expert Rev Neurother; 2019 Sep; 19(9):777-783. PubMed ID: 31389279
    [No Abstract]   [Full Text] [Related]  

  • 16. Brexpiprazole: a new leaf on the partial dopamine agonist branch.
    Hope J; Castle D; Keks NA
    Australas Psychiatry; 2018 Feb; 26(1):92-94. PubMed ID: 29017334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
    Davis LL; Ota A; Perry P; Tsuneyoshi K; Weiller E; Baker RA
    Brain Behav; 2016 Oct; 6(10):e00520. PubMed ID: 27781135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
    Aftab A; Gao K
    Expert Opin Drug Discov; 2017 Oct; 12(10):1067-1081. PubMed ID: 28718334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
    Antoun Reyad A; Girgis E; Mishriky R
    Int Clin Psychopharmacol; 2020 May; 35(3):119-128. PubMed ID: 32141908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder.
    Diefenderfer LA; Iuppa C
    Ment Health Clin; 2017 Sep; 7(5):207-212. PubMed ID: 29955525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.